Evidence map›Paper›PMID 34242082›Full record

ArticleJCO oncology practice2022

Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform.

Richard L Martin, Michael J Grant, Stephen Kimani, Shonali Midha, Jori May, Rushad Patell, Emily Collier, David Furfaro, Charles Bodine, Leo Reap and 21 more

Abstract read
In one paragraph

Article in JCO oncology practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Seeking Racial Equity in Hematology and Oncology: a Fellow-Led Educational Series to Promote Reflection and Action.Journal of cancer education : the official journal of the American Association for Cancer Education · 2023
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Richard L MartinDivision of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN.ORCID 0000-0001-7117-4954
Michael J GrantSection of Hematology-Oncology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT.
Stephen KimaniDepartment of Medicine, The University of North Carolina, Chapel Hill, NC.ORCID 0000-0003-0403-1296
Shonali MidhaH. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL.ORCID 0000-0003-4948-5507
Jori MayDivision of Hematology-Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Rushad PatellDivision of Hematology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-8426-3398
Emily CollierSection of Hematology-Oncology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT.
David FurfaroDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, New York-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY.ORCID 0000-0001-6514-699X
Charles BodineDivision of Hematology-Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Leo ReapDepartment of Medicine, Ascension Providence Hospital, Detroit, MI.ORCID 0000-0002-7421-2765
Nikesh ShahH. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL.ORCID 0000-0002-7558-9222
Jess DeLauneDivision of Hematology-Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL.ORCID 0000-0002-1171-9673
Samuel BruscaNational Institutes of Health Clinical Center, Bethesda, MD.ORCID 0000-0003-3762-7918
Coral OlazagastiDivision of Hematology-Oncology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra University, New Hyde Park, NY.ORCID 0000-0002-6658-0170
Shreya GoyalDivision of Hematology-Oncology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra University, New Hyde Park, NY.ORCID 0000-0002-8475-4787
Samuel RubinsteinDivision of Hematology, Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.ORCID 0000-0003-3065-9220
Nausheen HakimDivision of Hematology-Oncology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra University, Long Island, NY.
Shuai QinDivision of Hematology-Oncology, Department of Internal Medicine, Loyola University Medical Center, Maywood, IL.
Sabrina L BrowningDivision of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT.ORCID 0000-0002-9812-0654
Laura SenaThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Jill GilbertDivision of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN.
Mario DavidsonDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN.ORCID 0000-0002-5052-3438
Christine M LovlyDivision of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN.
Nagashree SeetharamuDivision of Hematology-Oncology, Donald and Barbara Zucker School of Medicine at Hofstra University, New Hyde Park, NY.ORCID 0000-0002-3282-7622
Deepa RangachariDivision of Hematology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Martina MurphyDivision of Hematology-Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL.
Monica ChatwalH. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL.ORCID 0000-0002-0358-1993
Rita PaschalDivision of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Elizabeth HenryDivision of Hematology-Oncology, Department of Internal Medicine, Department of Medical Education, Loyola University Medical Center, Maywood, IL.ORCID 0000-0003-2948-3985
Frances CollichioDivision of Hematology Oncology, Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.ORCID 0000-0001-9807-4240
Jennifer R GreenDivision of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

purposeCOVID-19 challenged medical practice and graduate medical education. Building on previous initiatives, we describe and reflect on the formative process and goals of the Hematology-Oncology Collaborative Videoconferencing Learning Initiative, a trainee-led multi-institutional virtual COVID-19 learning model.

methodsClinical fellows and faculty from 13 US training institutions developed consensus needs, goals, and objectives, recruited presenters, and generated a multidisciplinary COVID-19 curriculum. Weekly Zoom conferences consisted of two trainee-led instructional segments and a trainee-moderated faculty Q&A panel. Hematology-oncology training program faculty and trainees were the targeted audience. Leadership evaluations consisted of anonymized baseline and concluding mixed methods surveys. Presenter evaluations consisted of session debriefs and two structured focus groups. Conference evaluations consisted of attendance, demographics, and pre- or postmultiple-choice questions on topic learning objectives.

resultsIn 6 weeks, the initiative produced five conferences: antivirals, anticoagulation, pulmonology, provider resilience, and resource scarcity ethics. The average attendance was 100 (range 57-185). Among attendees providing both pre- and postconference data, group-level knowledge appeared to increase: antiviral (n = 46) pre-/postcorrect 82.6%/97.8% and incorrect 10.9%/2.2%, anticoagulation (n = 60) pre-/postcorrect 75%/93.3% and incorrect 15%/6.7%, and pulmonary (n = 21) pre-/postcorrect 66.7%/95.2% and incorrect 33.3%/4.8%. Although pulmonary management comfort appeared to increase, comfort managing of antivirals and anticoagulation was unchanged. At the conclusion of the pilot, leadership trainees reported improved self-confidence organizing multi-institutional collaborations, median (interquartile range) 58.5 (50-64) compared with baseline 34 (26-39), but did not report improved confidence in other educational or leadership skills.

conclusionDuring crisis, trainees built a multi-institutional virtual education platform for the purposes of sharing pandemic experiences and knowledge. Accomplishment of initiative goals was mixed. Lessons learned from the process and goals may improve future disaster educational initiatives.

Indexed as

COVID-19Education, DistanceHematologyHumansSARS-CoV-2Videoconferencing

Identifiers

PMID34242082
PMCPMC8758064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.